Tomoichiro Asano
1-2-3 Kasumi
Minami-ku
Hiroshima
734-8553
Japan
Name/email consistency: high
- Xanthine oxidoreductase is involved in macrophage foam cell formation and atherosclerosis development. Kushiyama, A., Okubo, H., Sakoda, H., Kikuchi, T., Fujishiro, M., Sato, H., Kushiyama, S., Iwashita, M., Nishimura, F., Fukushima, T., Nakatsu, Y., Kamata, H., Kawazu, S., Higashi, Y., Kurihara, H., Asano, T. Arterioscler. Thromb. Vasc. Biol. (2012)
- 4F2hc stabilizes GLUT1 protein and increases glucose transport activity. Ohno, H., Nakatsu, Y., Sakoda, H., Kushiyama, A., Ono, H., Fujishiro, M., Otani, Y., Okubo, H., Yoneda, M., Fukushima, T., Tsuchiya, Y., Kamata, H., Nishimura, F., Kurihara, H., Katagiri, H., Oka, Y., Asano, T. Am. J. Physiol., Cell Physiol. (2011)
- Erythrocytic sorbitol contents in diabetic patients correlate with blood aldose reductase protein contents and plasma glucose levels, and are normalized by the potent aldose reductase inhibitor fidarestat (SNK-860). Asano, T., Saito, Y., Kawakami, M., Yamada, N., Sekino, H., Hasegawa, S. J. Diabetes Complicat. (2004)
- Glucose transporter and Na+/glucose cotransporter as molecular targets of anti-diabetic drugs. Asano, T., Ogihara, T., Katagiri, H., Sakoda, H., Ono, H., Fujishiro, M., Anai, M., Kurihara, H., Uchijima, Y. Curr. Med. Chem. (2004)
- Fidarestat (SNK-860), a potent aldose reductase inhibitor, normalizes the elevated sorbitol accumulation in erythrocytes of diabetic patients. Asano, T., Saito, Y., Kawakami, M., Yamada, N. J. Diabetes Complicat. (2002)
- p110beta is up-regulated during differentiation of 3T3-L1 cells and contributes to the highly insulin-responsive glucose transport activity. Asano, T., Kanda, A., Katagiri, H., Nawano, M., Ogihara, T., Inukai, K., Anai, M., Fukushima, Y., Yazaki, Y., Kikuchi, M., Hooshmand-Rad, R., Heldin, C.H., Oka, Y., Funaki, M. J. Biol. Chem. (2000)